Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature

Gynecologic Oncology

Volumn 66, Issue 1, 1997, Pages 20-26

  Manetta, Alberto ^a   Tewari, Krishnansu ^a   Podczaski, Edward S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0031193915     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4725     Document Type: Article

References (39)

1. Manetta A, MacNeill C, Lyter J A, Scheffler B, Podczaski E S, Larson J E, Schein P. Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol. 36:1990;93-96.
2. Hoskins W, Perez C, Young R. Principles and Practice of Gynecologic Oncology. 1993;Lippencott, Philadelphia. p. 757-.
3. LIFETEST Procedure. 1972;. p. 529-557.
4. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
5. Ozols R F. Chemotherapy of ovarian cancer. Updates in Cancer: Principles and Practice of Oncology. 1988;. p. 1-.
6. Wharton J T. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer. Cancer Treatment Rev. 18:1991;15-21.
7. Smith J P, Rutledge F N. Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary. Natl Cancer Inst Monogr. 42:1975;169-172.
8. Young R C. Hexamethylmelamine (altretamine): Early National Cancer Institute trials. Cancer Treatment Rev. 18:1991;31-35.
9. Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: Long-term results. Cancer Treatment Rev. 18:1991;37-46.
10. Greco F A, Johnson D, Hainsworth J D. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. Cancer Treatment Rev. 18:1991;47-55.
11. Neijt J P, van Lindert A CM, Vendrik C PJ, Roozendaal K J, Struyvenberg A, Pinedo H M. Treatment of advanced ovarian carcinoma with a combination of hexamethylmelamine, cyclophosphamide, methotrexate, and 5-fluorouracil (Hexa-CAF) in patients with and without previous treatment. Cancer Treatment Rep. 64:1980;323-326.
12. Wiernik P H, Yeap B, Vogl S E, Kaplan B H, Comis R L, Falkson G, Davis T E, Fazzini E, Cheuvart B, Horton J. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: A study of the Eastern Cooperative Oncology Group. Cancer Invest. 10:1992;1-9.
13. Bruckner H W, Cohen C, Mandeli J, Chesser M R, Kabakow B, Wallach R, Holland J. Hexamethylmelamine for the treatment of ovarian cancer - The Mount Sinai experience. Cancer Treatment Rev. 18:1991;57-65.
14. Kristensen G B, Baekelandt M, Vergote I B, Trope C. A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Eur J Cancer. 31A:1995;1778-1780.
15. Frasci G, Comella G, Comella P, Conforti S, Mastrantonio P, Zullo F, Persico G. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: A phase II study. Gynecol Oncol. 58:1995;68-73.
16. Stanhope C R, Smith J P, Rutledge F. Second trial drugs in ovarian cancer. Gynecol Oncol. 5:1977;52-58.
17. Johnson B L, Fisher R I, Bender R A, De Vita V T Jr, Chabner B A, Young R C. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer. 42:1978;2157-2161.
18. Omura G A. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma. Cancer Treatment Rep. 65:1981;530-531.
19. Wampler G L, Mellete S J, Kupermine M, Regelson W. Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer. Cancer Chemother Rep. 56:1972;505-514.
20. Bonomi P D, Mladineo J, Morrin B, Wilbanks G Jr, Slayton R E. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treatment Rep. 63:1979;137-138.
21. Bolis G, D'Incalci M, Belloni C, Mangioni C. Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin. Cancer Treatment Rep. 63:1979;1375-1377.
22. Vogl S E, Pagano M, Kaplan B H, Einhorn N, Arseneau J, Moukhtar M, Greenwald E. Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-platinum, and doxorubicin after failure of prior therapy. Obstet Gynecol. 56:1980;635-640.
23. Tempero M A, Kessinger A. Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. J Surg Oncol. 21:1982;159-161.
24. Stehman F B, Ehrlich C E, Callaghan M F. Failure of hexamethylmelamine salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Gynecol Oncol. 17:1984;189-195.
25. Hauge M D, Long H J, Harmann L C, Edmonson J H, Webb M J, Su J. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest New Drugs. 10:1992;299-301.
26. Rosen G F, Lurain J R, Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol Oncol. 27:1987;173-179.
27. Moore D H, Fowler W C, Jones C P, Crumpler L S. Hexamethylmelamine chemotherapy for resistant or recurrent epithelial ovarian cancer. Am J Obstet Gynecol. 165:1991;573-576.
28. Fields A L, Schink J C, Miller D S, Rademaker A W, Lurain J R. Oral hexamethylmelamine: An effective salvage therapy for recurrent ovarian cancer. Int J Gynecol Obstet Abstract. 2048:1991;515.
29. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol. 47:1992;282-286.
30. Sipila P, Kivinen S, Grohn P, Vesala J, Heinonen E. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol. 34:1989;27-29.
31. Pater J L, Carmichael J A, Krepart G V, Fraser R C, Roy M, Kirk M E, Levitt M, Brown L.B, Wilson K S, Shelley W E. Second-line chemotherapy of Stage III-IV ovarian carcinoma: A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treatment Rep. 71:1987;277-281.
32. Belinson J L, Pretorius R G, McClure M, Ashikaga T. Hexamethylmelamine, methotrexate, 5-fluorouracil as second-line chemotherapy after platinum for epithelial ovarian malignancies. Gynecol Oncol. 23:1986;304-309.
33. Ozols R F, Garvin A J, Costa J, Simon R M, Young R C. Advanced ovarian cancer. Correlation of histologic grade with response to therapy and survival. Cancer. 45:1980;572-581.
34. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol. 10:1992;513-514.
35. Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma. Gynecol Oncol. 51:1993;104-106.
36. Thigpen J, Vance R, Khamsur F. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 71:1993;1559-1564.
37. McGuire W P, Rowinsky E K, Rosenshein N B, Grumbine F C, Ettinger D S, Armstrong D K, Donehower R C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 111:1989;273-279.
38. W, P, McQuire, W, J, Hoskins, M, F, Brady, P, R, Kucera, K, Y, Look, E, E, Patridge, M, Davidson, 1993, A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC), 255.
39. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.